Stipe Therapeutics

About Stipe Therapeutics

Stipe Therapeutics is a biotechnology company headquartered in Aarhus, Denmark, that is centered on harnessing the innate immune system to combat cancer. The company was established in 2018. It emerged from the foundational research conducted by its scientific founders at Aarhus University. The founders include Professor Søren R. Paludan from the Department of Biomedicine at Aarhus University, known for his work in immunology and inflammation; Dr. Martin Roelsgaard Jakobsen, an associate professor with a focus on innate immunity; and Dr. Jesper B. Bramsen, an associate professor specializing in molecular biology and genetics. Their collective academic background in innate immunity directly underpins the company's therapeutic approach.

The core of Stipe Therapeutics' strategy is the modulation of the Stimulator of Interferon Genes (STING) pathway, a critical component of the innate immune system that detects cytosolic DNA as a signal of infection or cellular damage. By activating this pathway within tumor cells, the company aims to initiate a powerful, localized anti-cancer immune response. This approach is designed to transform 'cold' tumors, which are non-responsive to immunotherapy, into 'hot' tumors that the immune system can recognize and attack. The company's lead product is a multi-target STING agonist, which means it can activate several points in the pathway simultaneously, potentially leading to a more robust and durable response compared to single-target agonists.

Stipe Therapeutics operates in the highly competitive immuno-oncology market, specifically targeting solid tumors. Its business model revolves around the research and development of novel therapeutics with the ultimate goal of bringing them to market, either independently or through strategic partnerships with larger pharmaceutical companies. The company has secured significant funding to advance its pipeline, including a EUR 20 million Series A financing round in 2019, co-led by Novo Holdings and Arix Bioscience plc. This capital is being used to progress its lead compound through preclinical studies and into initial clinical trials. The primary clients for its developed therapies would be oncology departments in hospitals and cancer treatment centers. The benefit of their approach lies in its potential to overcome resistance to existing cancer immunotherapies, thereby expanding the patient population that can benefit from these life-saving treatments.